Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Acarbose is again on the stage
Mustafa Altay, Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Keçiören Health Administration and Research Center, Keçiören 06290, Ankara, Turkey
Author contributions: Only Altay M contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mustafa Altay, MD, Chairman, Professor, Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Keçiören Health Administration and Research Center, Pınarbaşı District, Ardahan St. No. 25, Keçiören 06290, Ankara, Turkey. mustafa.altay@sbu.edu.tr
Received: March 31, 2021
Peer-review started: March 31, 2021
First decision: June 5, 2021
Revised: June 19, 2021
Accepted: December 22, 1021
Article in press: December 22, 1021
Published online: January 15, 2022
Processing time: 285 Days and 11.1 Hours
Peer-review started: March 31, 2021
First decision: June 5, 2021
Revised: June 19, 2021
Accepted: December 22, 1021
Article in press: December 22, 1021
Published online: January 15, 2022
Processing time: 285 Days and 11.1 Hours
Core Tip
Core Tip: The prevention of obesity and reducing cardiovascular risks, together with blood glucose control in patients with type 2 diabetes, are the main components of the treatment’s goals. New studies show that acarbose can provide the expected benefits of an ideal antidiabetic drug by increasing both insulin sensitivity and glucagon-like peptide 1 levels.